CoChat

Micafungin versus Caspofungin for Treatment of Candidemia and Other Forms of Invasive Candidiasis

Pappas, P. G., Rotstein, C. M. F., Betts, R. F., Nucci, M., Talwar, D., De Waele, J. J., Vazquez, J. A., Dupont, B. F., Horn, D. L., Ostrosky-Zeichner, L., Reboli, A. C., Suh, B., Digumarti, R., Wu, C., Kovanda, L. L., Arnold, L. J., Buell, D. N. · 2007 · Clinical Infectious Diseases

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Invasive candidiasis is an important cause of morbidity and mortality among patients with health care-associated infection. The echinocandins have potent fungicidal activity against most Candida species, but there are few data comparing the safety and efficacy of echinocandins in the treatment of invasive candidiasis. METHODS: This was an international, randomized, double-blind trial comparing micafungin (100 mg daily) and micafungin (150 mg daily) with a standard dosage of caspofungin (70 mg followed by 50 mg daily) in adults with candidemia and other forms of invasive candidiasis. The primary end point was treatment success, defined as clinical and mycological success at the end of blinded intravenous therapy. RESULTS: A total of 595 patients were randomized to one the treatment groups and received at least 1 dose of study drug. In the modified intent-to-treat population, 191 patients were assigned to the micafungin 100 mg group, 199 to the micafungin 150 mg group, and 188 to the caspofungin group. Demographic characteristics and underlying disorders were comparable across the groups. Approximately 85% of patients had candidemia; the remainder had noncandidemic invasive candidiasis. At the end of blinded intravenous therapy, treatment was considered successful for 76.4% of patients in the micafungin 100 mg group, 71.4% in the micafungin 150 mg group, and 72.3% in the caspofungin group. The median time to culture negativity was 2 days in the micafungin 100 mg group and the caspofungin group, compared with 3 days in the micafungin 150 mg groups. There were no significant differences in mortality, relapsing and emergent infections, or adverse events between the study arms. CONCLUSIONS: Dosages of micafungin 100 mg daily and 150 mg daily were noninferior to a standard dosage of caspofungin for the treatment of candidemia and other forms of invasive candidiasis.

Overview

Integrity signals

Registry

Crossref · 10.1086/520980

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 31 references

Research works printed but not linked: 1

  1. Mehrotra, 2000, Statistics in medicine, 19, 811, 10.1002/(SICI)1097-0258(20000330)19:6<811::AID-SIM390>3.0.CO;2-Z · doi:10.1002/(sici)1097-0258(20000330)19:6<811::aid-sim390>3.0.co;2-z

Cited by

Metadata

Authors
Pappas, P. G., Rotstein, C. M. F., Betts, R. F., Nucci, M., Talwar, D., De Waele, J. J., Vazquez, J. A., Dupont, B. F., Horn, D. L., Ostrosky-Zeichner, L., Reboli, A. C., Suh, B., Digumarti, R., Wu, C., Kovanda, L. L., Arnold, L. J., & Buell, D. N.
Affiliations
  • University of Alabama at Birmingham (US)
  • Hamilton Health Sciences (CA)
  • University of Rochester (US)
  • Hospital Universitário Clementino Fraga Filho (BR)
  • Government of Uttar Pradesh (IN)
  • Hôpital Necker-Enfants Malades (FR)
  • Thomas Jefferson University (US)
  • Cooper University Hospital (US)
  • Temple University (US)
  • Nizam's Institute of Medical Sciences (IN)
  • Astellas Pharma (United States) (US)
Corresponding author
Pappas, P. G.
Venue
Clinical Infectious Diseases
Published
2007-10-01
Volume
45
Issue
7
Pages
883-893
ISSN
  • 1058-4838 (ISSN-L)
  • 1537-6591
OpenAlex
W2139043187
Cited by
638
References
31
Citations by year
2026: 13 · 2025: 16 · 2024: 9 · 2023: 11 · 2022: 14 · 2021: 27 · 2020: 29 · 2019: 20 · 2018: 23 · 2017: 24 · 2016: 21 · 2015: 34 · 2014: 34 · 2013: 38 · 2012: 52
FWCI
40.96
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Infectious Diseases (publishedVersion)
  • PubMed (publishedVersion)
  • Ghent University Academic Bibliography (Ghent University) (submittedVersion)
Funders
Astellas Pharma
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
  • Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
Keywords
micafungin, caspofungin, invasive candidiasis, candidemia, echinocandins, antifungal drug comparison, dosing regimen, treatment success, mortality, relapse
MeSH terms
Caspofungin, Micafungin, Adolescent, Adult, Aged, Aged, 80 and over, Antifungal Agents, Candidiasis, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Lipoproteins, Male, Middle Aged, Peptides, Cyclic, Fungemia, Treatment Outcome, Echinocandins, Lipopeptides

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.